Dobutamine inhibits monocyte chemoattractant protein-1 production and chemotaxis in human monocytes

Chi Yuan Li, Chien Sung Tsai, Sheau Huei Chueh, Ping Ching Hsu, Jia Yi Wang, Chih Shung Wong, Shung Tai Ho

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

It has been reported that, in patients with acute myocardial infarction or congestive heart failure, monocyte chemoattractant protein-1 (MCP-1) plays an important role in the development of inflammatory responses and that the level of MCP-1 is correlated with the severity of the disease. We conducted this study to investigate the effects of dobutamine and dopamine on lipopolysaccharide (LPS)-induced MCP-1 production in human monocytic THP-1 cells. Monocytes were incubated in vitro with LPS for 16 h at 37°C in the presence or absence of dobutamine or dopamine. Enzyme-linked immunosorbent assay was used to examine the effect of dobutamine on MCP-1 synthesis, with the MCP-1 messenger RNA expression examined by reverse transcriptase-polymerase chain reaction. Dobutamine inhibited LPS-induced production of MCP-1, as well as messenger RNA expression, in a dose-dependent manner, whereas dopamine had no significant effect. Furthermore, we demonstrated that dobutamine suppressed MCP-1-induced chemotaxis and peak [Ca2+]i in monocytic THP-1 cells. These findings suggest that dobutamine may modulate monocyte activation, such as chemotaxis and [Ca2+]i, as well as MCP-1 production, during therapy for congestive heart failure.

Original languageEnglish
Pages (from-to)205-209
Number of pages5
JournalAnesthesia and Analgesia
Volume97
Issue number1
Publication statusPublished - Jul 1 2003
Externally publishedYes

Fingerprint

Dobutamine
Chemokine CCL2
Chemotaxis
Monocytes
Lipopolysaccharides
Dopamine
Heart Failure
Messenger RNA
Reverse Transcriptase Polymerase Chain Reaction
Enzyme-Linked Immunosorbent Assay
Myocardial Infarction

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Li, C. Y., Tsai, C. S., Chueh, S. H., Hsu, P. C., Wang, J. Y., Wong, C. S., & Ho, S. T. (2003). Dobutamine inhibits monocyte chemoattractant protein-1 production and chemotaxis in human monocytes. Anesthesia and Analgesia, 97(1), 205-209.

Dobutamine inhibits monocyte chemoattractant protein-1 production and chemotaxis in human monocytes. / Li, Chi Yuan; Tsai, Chien Sung; Chueh, Sheau Huei; Hsu, Ping Ching; Wang, Jia Yi; Wong, Chih Shung; Ho, Shung Tai.

In: Anesthesia and Analgesia, Vol. 97, No. 1, 01.07.2003, p. 205-209.

Research output: Contribution to journalArticle

Li, CY, Tsai, CS, Chueh, SH, Hsu, PC, Wang, JY, Wong, CS & Ho, ST 2003, 'Dobutamine inhibits monocyte chemoattractant protein-1 production and chemotaxis in human monocytes', Anesthesia and Analgesia, vol. 97, no. 1, pp. 205-209.
Li, Chi Yuan ; Tsai, Chien Sung ; Chueh, Sheau Huei ; Hsu, Ping Ching ; Wang, Jia Yi ; Wong, Chih Shung ; Ho, Shung Tai. / Dobutamine inhibits monocyte chemoattractant protein-1 production and chemotaxis in human monocytes. In: Anesthesia and Analgesia. 2003 ; Vol. 97, No. 1. pp. 205-209.
@article{fd5d92b7259f41a08d6d9d01ccc53c37,
title = "Dobutamine inhibits monocyte chemoattractant protein-1 production and chemotaxis in human monocytes",
abstract = "It has been reported that, in patients with acute myocardial infarction or congestive heart failure, monocyte chemoattractant protein-1 (MCP-1) plays an important role in the development of inflammatory responses and that the level of MCP-1 is correlated with the severity of the disease. We conducted this study to investigate the effects of dobutamine and dopamine on lipopolysaccharide (LPS)-induced MCP-1 production in human monocytic THP-1 cells. Monocytes were incubated in vitro with LPS for 16 h at 37°C in the presence or absence of dobutamine or dopamine. Enzyme-linked immunosorbent assay was used to examine the effect of dobutamine on MCP-1 synthesis, with the MCP-1 messenger RNA expression examined by reverse transcriptase-polymerase chain reaction. Dobutamine inhibited LPS-induced production of MCP-1, as well as messenger RNA expression, in a dose-dependent manner, whereas dopamine had no significant effect. Furthermore, we demonstrated that dobutamine suppressed MCP-1-induced chemotaxis and peak [Ca2+]i in monocytic THP-1 cells. These findings suggest that dobutamine may modulate monocyte activation, such as chemotaxis and [Ca2+]i, as well as MCP-1 production, during therapy for congestive heart failure.",
author = "Li, {Chi Yuan} and Tsai, {Chien Sung} and Chueh, {Sheau Huei} and Hsu, {Ping Ching} and Wang, {Jia Yi} and Wong, {Chih Shung} and Ho, {Shung Tai}",
year = "2003",
month = "7",
day = "1",
language = "English",
volume = "97",
pages = "205--209",
journal = "Anesthesia and Analgesia",
issn = "0003-2999",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Dobutamine inhibits monocyte chemoattractant protein-1 production and chemotaxis in human monocytes

AU - Li, Chi Yuan

AU - Tsai, Chien Sung

AU - Chueh, Sheau Huei

AU - Hsu, Ping Ching

AU - Wang, Jia Yi

AU - Wong, Chih Shung

AU - Ho, Shung Tai

PY - 2003/7/1

Y1 - 2003/7/1

N2 - It has been reported that, in patients with acute myocardial infarction or congestive heart failure, monocyte chemoattractant protein-1 (MCP-1) plays an important role in the development of inflammatory responses and that the level of MCP-1 is correlated with the severity of the disease. We conducted this study to investigate the effects of dobutamine and dopamine on lipopolysaccharide (LPS)-induced MCP-1 production in human monocytic THP-1 cells. Monocytes were incubated in vitro with LPS for 16 h at 37°C in the presence or absence of dobutamine or dopamine. Enzyme-linked immunosorbent assay was used to examine the effect of dobutamine on MCP-1 synthesis, with the MCP-1 messenger RNA expression examined by reverse transcriptase-polymerase chain reaction. Dobutamine inhibited LPS-induced production of MCP-1, as well as messenger RNA expression, in a dose-dependent manner, whereas dopamine had no significant effect. Furthermore, we demonstrated that dobutamine suppressed MCP-1-induced chemotaxis and peak [Ca2+]i in monocytic THP-1 cells. These findings suggest that dobutamine may modulate monocyte activation, such as chemotaxis and [Ca2+]i, as well as MCP-1 production, during therapy for congestive heart failure.

AB - It has been reported that, in patients with acute myocardial infarction or congestive heart failure, monocyte chemoattractant protein-1 (MCP-1) plays an important role in the development of inflammatory responses and that the level of MCP-1 is correlated with the severity of the disease. We conducted this study to investigate the effects of dobutamine and dopamine on lipopolysaccharide (LPS)-induced MCP-1 production in human monocytic THP-1 cells. Monocytes were incubated in vitro with LPS for 16 h at 37°C in the presence or absence of dobutamine or dopamine. Enzyme-linked immunosorbent assay was used to examine the effect of dobutamine on MCP-1 synthesis, with the MCP-1 messenger RNA expression examined by reverse transcriptase-polymerase chain reaction. Dobutamine inhibited LPS-induced production of MCP-1, as well as messenger RNA expression, in a dose-dependent manner, whereas dopamine had no significant effect. Furthermore, we demonstrated that dobutamine suppressed MCP-1-induced chemotaxis and peak [Ca2+]i in monocytic THP-1 cells. These findings suggest that dobutamine may modulate monocyte activation, such as chemotaxis and [Ca2+]i, as well as MCP-1 production, during therapy for congestive heart failure.

UR - http://www.scopus.com/inward/record.url?scp=0037636177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037636177&partnerID=8YFLogxK

M3 - Article

C2 - 12818967

AN - SCOPUS:0037636177

VL - 97

SP - 205

EP - 209

JO - Anesthesia and Analgesia

JF - Anesthesia and Analgesia

SN - 0003-2999

IS - 1

ER -